Arlene Morris Net Worth

The estimated Net Worth of Arlene Morris is at least $746 Thousand dollars as of 20 November 2018. Ms. Morris owns over 12,000 units of Unum Therapeutics stock worth over $679,148 and over the last 18 years she sold UMRX stock worth over $0. In addition, she makes $67,190 as Independent Director at Unum Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Morris UMRX stock SEC Form 4 insiders trading

Arlene has made over 3 trades of the Unum Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently she bought 12,000 units of UMRX stock worth $8,280 on 20 November 2018.

The largest trade she's ever made was exercising 20,000 units of Unum Therapeutics stock on 9 June 2016 worth over $47,000. On average, Arlene trades about 907 units every 45 days since 2007. As of 20 November 2018 she still owns at least 288,999 units of Unum Therapeutics stock.

You can see the complete history of Ms. Morris stock trades at the bottom of the page.

Arlene Morris biography

Arlene M. Morris serves as Independent Director of the Company. Ms. Morris has served as a member of our Board of Directors since July 2019. Ms. Morris has served as Chief Executive Officer of Willow Advisors, a consultancy advising biotech companies on financing, strategy and business development, since 2015. Previously, she spent over a decade leading public biotechnology companies. From 2012 to 2015, Ms. Morris served as Chief Executive Officer of Syndax Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers. Prior to this she served as President and Chief Executive Officer of Affymax, where she led the company through the development of peginesatide (Omontys®). She is currently a member of the Board of Directors of Viveve (Nasdaq: VIVE), Palatin Technologies (NYSE: PTN), MiRagen Therapeutics, Inc. (Nasdaq: MGEN), and Neovacs, SA (Euronext: ALNEV).

What is the salary of Arlene Morris?

As the Independent Director of Unum Therapeutics, the total compensation of Arlene Morris at Unum Therapeutics is $67,190. There are 1 executives at Unum Therapeutics getting paid more, with Karen Ferrante having the highest compensation of $67,482.

How old is Arlene Morris?

Arlene Morris is 68, she's been the Independent Director of Unum Therapeutics since 2019. There are no older and 7 younger executives at Unum Therapeutics.

What's Arlene Morris's mailing address?

Arlene's mailing address filed with the SEC is PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512.

Insiders trading at Unum Therapeutics

Over the last 7 years, insiders at Unum Therapeutics have traded over $0 worth of Unum Therapeutics stock and bought 1,283,156 units worth $11,122,392 . The most active insiders traders include Llc Fmr, Liam Ratcliffe, and Bruce Booth. On average, Unum Therapeutics executives and independent directors trade stock every 72 days with the average trade being worth of $286,216. The most recent stock trade was executed by Healthcare Capital Partners... on 14 August 2020, trading 451,000 units of UMRX stock currently worth $1,136,520.

What does Unum Therapeutics do?

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Complete history of Ms. Morris stock trades at Medicinova Inc, Miragen Therapeutics Inc, Viveve Medical Inc, Palatin Technologies, and Unum Therapeutics

Unum Therapeutics executives and stock owners

Unum Therapeutics executives and other stock owners filed with the SEC include:

• Karen Ferrante,
  Independent Director
• Arlene Morris,
  Independent Director
• Matthew Ros,
  Independent Director
• Stephanie Ascher,
  Investor Relations
• Peter Harwin,
  Director
• Chris Cain,
  Director
• Jessica Sachs,
  Chief Medical Officer
• John Green,
  Chief Financial Officer, Vice President - Finance, Controller
• Andrew Robbins,
  President, Chief Executive Officer and Principal Executive Officer, Director
• Llc Fmr,
  
• Bruce Booth,
  Director
• Funds Management Llc Fairmount,
  10% owner
• Ltd Fil,
  
• Venture Fund Ix, L.P.Atlas ...,
  
• Liam Ratcliffe,
  Director
• Jorn Aldag,
  Director
• Robert J Perez,
  Director
• Seth Ettenberg,
  Chief Scientific Officer
• Geoffrey Hodge,
  Chief Technical Officer
• Charles Wilson,
  Chief Executive Officer
• Michael Vasconcelles,
  Chief Medical Officer
• Matthew Scott Osborne,
  Chief Financial Officer
• Healthcare Capital Partners...,